BioLargo Inc

BioLargo Inc.: promising PFAS‑cleaning tech meets declining stock and negative P/E, raising investor concerns.

BioLargo’s new AEC PFAS treatment system at Lake Stockholm demonstrates its cutting‑edge environmental tech, while volatile stock and loss‑making status highlight growth risks and investment potential.

BioLargo Inc. invites investors to its Q3 2025 earnings call, revealing PFAS remediation breakthroughs, a new ViaCLYR™ wound‑care partnership, and growth prospects across environmental and medical markets.

BioLargo Inc. has reported a 517% increase in revenue in its engineering segment, driven by growth in air quality control services, and has also made significant advancements in its technology sectors, including a major distribution agreement for it…

BioLargo Inc. has made significant strides in 2025, achieving strategic milestones in cleantech and life sciences, positioning the company for continued growth and success in addressing environmental challenges.

BioLargo Inc. celebrates a year of breakthroughs and strategic achievements in environmental solutions, positioning itself for future success in the cleantech and life sciences sectors.

BioLargo Inc. focuses on developing innovative environmental solutions, but faces financial challenges and a negative price-to-earnings ratio.

BioLargo Inc’s financial performance is a cause for concern, with a plummeting stock price and negative price-to-earnings ratio, despite its innovative environmental solutions and commitment to sustainability.

BioLargo Inc. is set to announce its Q1 2025 earnings on May 15, 2025, with a webcast and conference call that will provide insights into the company’s financial performance and strategic direction.

BioLargo, Inc. has been making headlines with its innovative environmental solutions, including PFAS treatment, and has experienced significant stock price volatility over the past year.